Related references
Note: Only part of the references are listed.Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1
Francois Dabis
AIDS (2009)
Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission
Benjamin H. Chi et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2008)
Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa
G. U. van Zyl et al.
JOURNAL OF MEDICAL VIROLOGY (2008)
Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial
Benjamin H. Chi et al.
LANCET (2007)
Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1:: a meta-analysis
Elise Arrive et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2007)
Reducing the risk of mother-to-child human immunodeficiency virus transmission: past successes, current progress and challenges, and future directions
Mary Glenn Fowler et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2007)
Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine
Neil A. Martinson et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2007)
Response to antiretroviral therapy after a single, peripartum dose of nevirapine
Shahin Lockman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission
S Palmer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire
ML Chaix et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine - Implications for intervention studies
E Muro et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2005)
Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated
JA Johnson et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N Nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012
T Flys et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP
SH Eshleman et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy
G Jourdain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial
JB Jackson et al.
LANCET (2003)
A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1
D Moodley et al.
JOURNAL OF INFECTIOUS DISEASES (2003)
Impact of human immunodeficiency virus type 1 (HIV-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent HIV-1 vertical transmission (HIV Network for Prevention Trials 012 study)
SH Eshleman et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
Share Paper
